

Mohsen Farsad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6030790/publications.pdf>

Version: 2024-02-01

61
papers

2,802
citations

257450

24
h-index

189892

50
g-index

67
all docs

67
docs citations

67
times ranked

3046
citing authors

#	ARTICLE	IF	CITATIONS
1	Lifelong bilingualism and mechanisms of neuroprotection in Alzheimer dementia. Human Brain Mapping, 2022, 43, 581-592.	3.6	7
2	10-Year Clinical Experience With 18F-Choline PET/CT. Clinical Nuclear Medicine, 2020, 45, 594-603.	1.3	6
3	The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lung cancer (NSCLC). Clinical and Translational Imaging, 2020, 8, 29-38.	2.1	0
4	FDG PET/CT in the Staging of Lung Cancer. Current Radiopharmaceuticals, 2020, 13, 195-203.	0.8	28
5	Economic sanctions are against basic human rights on health. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1046-1047.	6.4	2
6	Non-FDG PET/CT in Diagnostic Oncology: a pictorial review. European Journal of Hybrid Imaging, 2019, 3, 20.	1.5	10
7	Cancers of Unknown Origin. , 2018, , 319-328.		0
8	Infection and Inflammation. , 2018, , 331-346.		0
9	Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1898-1907.	6.4	17
10	Risk-related 18F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1908-1914.	6.4	12
11	Head and Neck Malignancies. , 2018, , 167-191.		0
12	Malignancy in Orthopedics. , 2018, , 305-318.		0
13	Premises to PET/CT with FDG in Oncology. , 2018, , 3-17.		0
14	Malignancies of Lower Gastroenterological Tract. , 2018, , 259-290.		0
15	Malignancies in Hematology. , 2018, , 77-101.		0
16	The impact of bilingualism on brain reserve and metabolic connectivity in Alzheimer's dementia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1690-1695.	7.1	164
17	Value of Fused ¹⁸ F-Choline-PET/MRI to Evaluate Prostate Cancer Relapse in Patients Showing Biochemical Recurrence after EBRT: Preliminary Results. BioMed Research International, 2014, 2014, 1-9.	1.9	44
18	FDG PET/CT in Malignant Eccrine Porocarcinoma Arising in a Pre-existing Poroma. Clinical Nuclear Medicine, 2014, 39, 456-458.	1.3	7

#	ARTICLE	IF	CITATIONS
19	¹⁸ F-DOPA and ¹⁸ F-FDG PET/CT, Scintigraphic Localization and Radioguided Surgery of Recurrent Medullary Thyroid Cancer: Two Case Reports. <i>Current Radiopharmaceuticals</i> , 2014, 7, 133-137.	0.8	3
20	Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation. <i>Annals of Hematology</i> , 2013, 92, 121-123.	1.8	9
21	Mesenteric panniculitis presenting with acute non-occlusive colonic ischemia. <i>International Archive of Medicine</i> , 2011, 4, 22.	1.2	12
22	Clinical Aspects, Diagnostic Challenges and Management of Patients with Neuroendocrine Tumors (NETs). <i>Onkologie</i> , 2011, 34, 139-146.	0.8	4
23	Imaging with ¹¹ Carbon labelled PET tracers. <i>Nuclear Medicine Communications</i> , 2010, 31, 613-616.	1.1	3
24	Choline PET-CT. , 2010, , 13-47.		0
25	Acetate PET-CT. , 2010, , 123-143.		1
26	¹¹ C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>Tumori</i> , 2009, 95, 382-384.	1.1	28
27	Thromboembolism in Pulmonary Artery Sarcoma. <i>Clinical Nuclear Medicine</i> , 2009, 34, 239-240.	1.3	17
28	C-11 Acetate Does Not Enhance Usefulness of F-18 FDG PET/CT in Differentiating Between Focal Nodular Hyperplasia and Hepatic Adenoma. <i>Clinical Nuclear Medicine</i> , 2009, 34, 659-665.	1.3	21
29	394 DIFFERENTIAL DIAGNOSIS BETWEEN FOCAL NODULAR HYPERPLASIA AND HEPATOCELLULAR ADENOMA: POTENTIAL ROLE OF DOUBLE TRACER PET WITH ¹¹ C-ACETATE AND ¹⁸ F-FDG. <i>Journal of Hepatology</i> , 2008, 48, S153.	3.7	0
30	Molecular Imaging Suggests Efficacy of Bevacizumab beyond the Second Line in Advanced Colorectal Cancer Patients. <i>Chemotherapy</i> , 2008, 54, 421-424.	1.6	13
31	Reliability and reproducibility of N-[¹¹ C]methyl-choline and L-(S-methyl-[¹¹ C])methionine solid-phase synthesis: a useful and suitable method in clinical practice. <i>Nuclear Medicine Communications</i> , 2008, 29, 736-740.	1.1	14
32	Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and ¹¹ C-Choline PET/CT. <i>Radiology</i> , 2007, 244, 797-806.	7.3	193
33	Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. <i>Haematologica</i> , 2007, 92, 771-777.	3.5	74
34	Role of ¹⁸ F-dopa PET/CT imaging in the management of patients with ¹¹¹ In-pentetreotide negative GEP tumours. <i>Nuclear Medicine Communications</i> , 2007, 28, 473-477.	1.1	45
35	Diagnostic accuracy of ¹⁸ F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. <i>Nuclear Medicine Communications</i> , 2007, 28, 589-595.	1.1	168
36	¹¹ C-choline vs. ¹⁸ F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 68.	1.9	97

#	ARTICLE	IF	CITATIONS
37	Predictive Role of Positron Emission Tomography in the Outcome of Patients with Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 291-295.	1.4	44
38	A simple Tracerlab module modification for automated on-column [11C]methylation and [11C]carboxylation. <i>Applied Radiation and Isotopes</i> , 2007, 65, 691-695.	1.5	25
39	FDG small animal PET permits early detection of malignant cells in a xenograft murine model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 755-762.	6.4	25
40	11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1704-1705.	6.4	25
41	¹¹ C-Choline Positron Emission Tomography/Computerized Tomography for Tumor Localization of Primary Prostate Cancer in Comparison With 12-Core Biopsy. <i>Journal of Urology</i> , 2006, 176, 954-960.	0.4	144
42	18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2096-2101.	1.3	54
43	Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-d-glucose uptake in heavily pre-treated lymphoma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 1048-1052.	1.3	5
44	Role of ¹⁸ F-FDG-PET and PET/CT imaging in thyroid cancer. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 409-413.	5.6	46
45	¹⁸ F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 593-606.	5.6	32
46	Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 525-531.	6.4	135
47	¹¹ C-methionine PET/CT in ^{99m} Tc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 453-459.	6.4	49
48	Incidental finding of an ¹¹ C-choline PET-positive solitary plasmacytoma lesion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1522-1522.	6.4	17
49	¹⁸ F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. <i>Radiologia Medica</i> , 2006, 111, 1146-1155.	7.7	47
50	Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at ¹⁸ F-FDG-PET/CT: an unusual finding. <i>Cancer Imaging</i> , 2006, 6, 20-23.	2.8	21
51	Artefacts of PET/CT images. <i>Biomedical Imaging and Intervention Journal</i> , 2006, 2, e60.	0.5	13
52	Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. <i>Nuclear Medicine Communications</i> , 2005, 26, 689-694.	1.1	88
53	Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. <i>Nuclear Medicine Communications</i> , 2005, 26, 827-830.	1.1	31
54	¹⁸ F-FDG PET in malignant lymphoma: significance of positive findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 749-756.	6.4	62

#	ARTICLE	IF	CITATIONS
55	Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology, 2005, 46, 1076-1084.	2.8	674
56	Role of 18f-FDG PET/CT in the Management of Multiple Myeloma.. Blood, 2005, 106, 3492-3492.	1.4	0
57	Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. Journal of Nuclear Medicine, 2005, 46, 1642-9.	5.0	178
58	Role of 18F-FDG PET for Evaluating Malignant Pleural Mesothelioma. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 149-154.	1.0	30
59	¹⁸ F-FDG PET Early After Radiotherapy in Lymphoma Patients. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 606-612.	1.0	24
60	Scintigraphic Findings in Necrotizing Myopathy. Clinical Nuclear Medicine, 2003, 28, 118-120.	1.3	1
61	Somatostatin Receptor Scintigraphy for Bronchial Carcinoid Follow-Up. Clinical Nuclear Medicine, 2003, 28, 548-552.	1.3	32